Information Provided By:
Fly News Breaks for February 4, 2020
Feb 4, 2020 | 07:32 EDT
Goldman Sachs analyst Paul Choi assumed coverage of Allakos with a Neutral rating with a price target of $94, up from $89. The analyst is positive on AK002, the company's monoclonal antibody being developed initially for certain gastrointestinal disease indications.
News For ALLK From the Last 2 Days
There are no results for your query ALLK